Invention Application
- Patent Title: Use of Specifically Engineered Enzymes to Enhance the Efficacy of Prodrugs
- Patent Title (中): 使用专门设计的酶来提高前药的功效
-
Application No.: US11760399Application Date: 2007-06-08
-
Publication No.: US20070258968A1Publication Date: 2007-11-08
- Inventor: Arnon Lavie , Manfred Konrad , Farhad Ravandi
- Applicant: Arnon Lavie , Manfred Konrad , Farhad Ravandi
- Applicant Address: US IL Urbana
- Assignee: The Board of Trustees of the University of Illinois
- Current Assignee: The Board of Trustees of the University of Illinois
- Current Assignee Address: US IL Urbana
- Main IPC: A61K38/00
- IPC: A61K38/00 ; C07H21/00 ; C12N15/00 ; C12N5/06 ; C12N9/12 ; C12P1/00
Abstract:
The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention provides antibody-conjugated enzymes that can be specifically delivered to leukemic blast cells in vivo or ex vivo.
Public/Granted literature
- US07858745B2 Use of specifically engineered enzymes to enhance the efficacy of prodrugs Public/Granted day:2010-12-28
Information query
IPC分类:
